TY - ADVS
T1 - PEARL Trial in Metastatic Breast Cancer: Palbociclib Plus Endocrine Therapy Versus Capecitabine
AU - Cutter, Noelle L
N1 - By: Noelle Cutter, PhD Posted: Tuesday, March 9, 2021 To better understand the efficacy of palbociclib plus endocrine therapy compared with that of chemotherapy alone, the phase III PEARL trial was conducted.
PY - 2021/3/9
Y1 - 2021/3/9
N2 - To better understand the efficacy of palbociclib plus endocrine therapy compared with that of chemotherapy alone, the phase III PEARL trial was conducted. The findings of this study, published in Annals of Oncology, suggest that the palbociclib combination does not show improved progression-free survival compared with chemotherapy alone in hormone receptor–positive HER2-negative, metastatic breast cancer who were resistant to aromatase inhibitors. However, a better safety profile and improved quality of life with the palbociclib combination therapy were reported by Miguel Martin, MD, PhD, of Gregorio Marañón Institute in Madrid, and colleagues.
AB - To better understand the efficacy of palbociclib plus endocrine therapy compared with that of chemotherapy alone, the phase III PEARL trial was conducted. The findings of this study, published in Annals of Oncology, suggest that the palbociclib combination does not show improved progression-free survival compared with chemotherapy alone in hormone receptor–positive HER2-negative, metastatic breast cancer who were resistant to aromatase inhibitors. However, a better safety profile and improved quality of life with the palbociclib combination therapy were reported by Miguel Martin, MD, PhD, of Gregorio Marañón Institute in Madrid, and colleagues.
UR - https://jnccn360.org/breast/medical-literature/pearl-trial-in-metastatic-breast-cancer-palbociclib-plus-endocrine-therapy-versus-capecitabine/
M3 - Web publication/site
ER -